Current medical research and opinion
-
To compare real-world adherence to and persistence with deferasirox film-coated tablets (DFX-FCT) and deferasirox dispersible tablets (DFX-DT) among patients who switched from DFX-DT to DFX-FCT, overall and by disease type (sickle cell disease [SCD], thalassemia, and myelodysplastic syndrome [MDS]). ⋯ Adherence and persistence improved significantly after switching from DFX-DT to DFX-FCT for all diseases, but especially MDS.